A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10381 in Patients With Advanced Solid Tumors
Latest Information Update: 11 Jul 2022
At a glance
- Drugs HS 10381 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 04 Jul 2022 Status changed from not yet recruiting to recruiting.
- 24 May 2022 New trial record